A detailed history of State Street Corp transactions in Maxcyte, Inc. stock. As of the latest transaction made, State Street Corp holds 2,269,135 shares of MXCT stock, worth $7.76 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,269,135
Previous 2,158,069 5.15%
Holding current value
$7.76 Million
Previous $8.46 Million 4.34%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.68 - $5.06 $408,722 - $561,993
111,066 Added 5.15%
2,269,135 $8.83 Million
Q2 2024

Aug 14, 2024

BUY
$3.63 - $5.0 $626,338 - $862,725
172,545 Added 8.69%
2,158,069 $8.46 Million
Q1 2024

May 15, 2024

BUY
$3.94 - $5.38 $163,616 - $223,415
41,527 Added 2.14%
1,985,524 $8.32 Million
Q4 2023

Feb 14, 2024

BUY
$2.6 - $5.24 $269,939 - $544,032
103,823 Added 5.64%
1,943,997 $9.14 Million
Q3 2023

Nov 14, 2023

BUY
$3.02 - $5.1 $83,956 - $141,780
27,800 Added 1.53%
1,840,174 $5.74 Million
Q2 2023

Aug 14, 2023

BUY
$3.69 - $5.35 $67,250 - $97,503
18,225 Added 1.02%
1,812,374 $8.32 Million
Q1 2023

May 15, 2023

BUY
$4.03 - $5.89 $10,405 - $15,207
2,582 Added 0.14%
1,794,149 $8.88 Million
Q4 2022

Feb 14, 2023

BUY
$4.92 - $7.4 $221,685 - $333,429
45,058 Added 2.58%
1,791,567 $9.78 Million
Q3 2022

Nov 15, 2022

BUY
$4.52 - $6.51 $857,959 - $1.24 Million
189,814 Added 12.19%
1,746,509 $11.4 Million
Q2 2022

Aug 15, 2022

SELL
$3.59 - $6.81 $21,773 - $41,302
-6,065 Reduced 0.39%
1,556,695 $7.36 Million
Q1 2022

May 16, 2022

BUY
$5.26 - $10.84 $1.33 Million - $2.73 Million
252,201 Added 19.24%
1,562,760 $10.9 Million
Q4 2021

Feb 14, 2022

BUY
$8.87 - $12.94 $10.8 Million - $15.8 Million
1,219,183 Added 1334.25%
1,310,559 $13.4 Million
Q3 2021

Nov 15, 2021

BUY
$12.21 - $17.2 $1.12 Million - $1.57 Million
91,376 New
91,376 $1.12 Million

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $348M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.